Key result
CD248-targeted BBIR-T cell therapy administered after scar maturation effectively cleared late-activated fibroblasts, inhibited fibrotic expansion in the peri-infarct zone, and improved cardiac function in a mouse model of myocardial infarction.
Why the study?
Excessive cardiac fibrosis driven by abnormally activated fibroblasts after scar maturation causes heart failure and adverse ventricular remodeling after myocardial infarction.
Does CD248-targeted BBIR-T cell therapy improve cardiac function and reduce fibrosis in a mouse model of myocardial infarction?
Does CD248-targeted BBIR-T cell therapy improve cardiac function and reduce fibrosis in a mouse model of myocardial infarction?
A novel CD248-targeted BBIR-T cell therapy targeting late-activated fibroblasts reduces cardiac fibrosis and improves function post-myocardial infarction in mice.
Answers are grounded in this paper and cite their sources.
Supports preclinical testing of fibroblast-targeted T cells post-MI; leaves open survival benefit and human translation.
Excessive cardiac fibrosis is a key cause of heart failure and adverse ventricular remodeling after myocardial infarction. The abnormally activated fibroblasts after scar maturation are the chief culprit. Single-cell RNA sequencing of mouse cardiac interstitial cells after myocardial infarction depicts a late-activated fibroblast subpopulation F-Act and initially identifies its characteristic antigen CD248, which is also verified in human hearts. On this basis, we develop a CD248-targeted biotin-binding immune receptor T cell therapy against F-Act to correct cardiac repair disorders. In our study, the precise removal of F-Act after the scar matured effectively inhibits fibrotic expansion in the peri-infarct zone and improves cardiac function. This therapy provides an idea for the treatment of cardiac fibrosis and also promotes the application of engineered T cells to non-tumor diseases. Abnormal activation of fibroblasts in mature scars after myocardial infarction is a key etiological factor in tissue repair disorders. Here, the authors developed a BBIR-T cell therapy that precisely targets pathogenic fibroblast subpopulations, thereby delaying ventricular remodeling and deterioration of cardiac function.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied Myocardial infarction. CD248-targeted BBIR-T cell therapy vs. Sham, MI+BF, MI+BF+Activated T, MI+BBIR-T, MI+BF+anti-CD19 CAR-T was evaluated on Cardiac function (LVEF, LVFS) and fibrosis expansion. CD248-targeted BBIR-T cell therapy administered after scar maturation effectively cleared late-activated fibroblasts, inhibited fibrotic expansion in the peri-infarct zone, and improved cardiac function in a mouse model of myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: